Trials
2 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- IgA Nephropathy (IgAN), C3 Glomerulopathy, IC-MPGN, PNH - Paroxysmal Nocturnal Hemoglobinuria
- Main trialPhase 2
- “This study looks at how well and safely SGB-9768 works for patients with certain kidney diseases: primary IgA nephropathy, C3 glomerulopathy, and immune complex-related membranoproliferative glomerulonephritis. It's a phase 2 trial done at several locations where both patients and doctors know what treatment is being given.”In the company’s words, NCT06786338 on ClinicalTrials.gov
Other drugs for IgA Nephropathy (IgAN)
- HSK39297Haisco Pharmaceutical Group Co., Ltd. · Phase 3
- SC0062Biocity Biopharmaceutics Co., Ltd. · Phase 3
- FelzartamabBiogen · Phase 3
- ZigakibartNovartis · Phase 3
- HRS-5965Hengrui · Phase 3
- IptacopanNovartis · Phase 3
Coming up2
- 29 DecPhase 2 trial completes · ClinicalTrials.gov
- 31 Aug 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 29 Dec 2026 | A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases | |
| Phase 2Not yet recruiting | 31 Aug 2027 | Study of SGB-9768 in Patients With Paroxysmal Nocturnal Hemoglobinuria | |
| Phase 1Completed | 7 May 2026 | A Study of SGB-9768 in Adult Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026